Injectable Glutathione Derivatives Bypass Oral Bioavailability Limits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for increasing glutathione levels in individuals with deficiencies or disorders are ineffective and often associated with side effects, as oral bioavailability is poor and glutathione injection does not directly or sufficiently raise intracellular levels, while patients with impaired transsulfuration pathways or malabsorption issues struggle to obtain essential amino acids.
Innovation Solution
Development of cell membrane permeable glutathione derivatives such as glutathione esters and gamma-glutamylcysteine esters that can cross cellular membranes to increase intracellular glutathione levels, bypassing enzymatic inefficiencies and providing alternative sources of cysteine and glutathione precursors through injectable formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oral cysteine supplementation is used to increase glutathione production, then glutathione levels may improve, but oral bioavailability is poor and absorption is limited
Solution Approach 1:
The patent uses injectable formulations of cysteine, gamma-glutamylcysteine, or glutathione as intermediary compounds that bypass the oral absorption barrier. These intermediaries are administered parenterally to directly increase intracellular glutathione levels, resolving the contradiction between improving glutathione production and overcoming poor oral bioavailability
Solution Approach 2:
The patent changes the administration route parameter from oral to parenteral (intravenous or intramuscular injection). This parameter change eliminates the absorption barrier entirely, allowing 100% bioavailability of the cysteine precursors and their conversion to glutathione, thus resolving the contradiction between quantity of substance and ease of operation
2Object-affected harmful factors
If L-cysteine injection is administered to reduce oxidative damage, then glutathione production increases, but cysteine can oxidize to insoluble cystine and become toxic at high levels
Solution Approach 1:
The patent introduces gamma-glutamylcysteine as an intermediary compound that serves as a protected form of cysteine. This intermediary is more stable, less prone to oxidation, and can be efficiently converted to glutathione intracellularly, thus reducing oxidative damage without generating the harmful effects of free cysteine oxidation
Solution Approach 2:
The patent converts the potential harm of cysteine oxidation into a benefit by using cysteine derivatives (such as glutathione esters or gamma-glutamylcysteine) that are designed to be oxidation-resistant. These derivatives safely deliver cysteine equivalents to cells without undergoing harmful oxidation, transforming the oxidation problem into a solution
3Quantity of substance
If glutathione is injected directly into the bloodstream, then systemic glutathione levels increase, but glutathione is not readily taken into cells and has a short half-life
Solution Approach 1:
The patent applies preliminary action by administering cysteine or gamma-glutamylcysteine precursors before the cell needs glutathione. These precursors are taken up by cells and stored or converted to glutathione intracellularly, ensuring glutathione is available when needed and extending its effective duration of action
Solution Approach 2:
The patent uses cysteine and gamma-glutamylcysteine as intermediary precursors that serve as stable, cell-permeable forms of glutathione delivery. These intermediaries have longer half-lives in circulation and can be converted to active glutathione intracellularly, resolving the contradiction between increasing systemic levels and extending duration of action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives effectively and safely increase intracellular glutathione levels, providing a rapid and controlled increase in glutathione, which can be maintained over time, addressing deficiencies and disorders like homocystinuria and liver disease, and enhancing overall health and oxidative stress protection.
Implementation Method 1
cell membrane permeable prodrug or derivative of cysteine, glutamylcysteine, and or glutathione
Data Source
AI summary
Methods, formulations, and applications of increasing intracellular glutathione levels with at least one injectable cell membrane permeable prodrug or derivative of cysteine, glutamylcysteine, glutathione, or a combination thereof, to treat, reduce, or prevent cellular and tissue oxidative damage, to increase levels of amino acids, and to treat numerous disease states and conditions including inborn errors of metabolism, nutritional malabsorption, and aging.